Among new treatment approaches for patients with cancer, few have accelerated as quickly
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …

Background Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts
and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

PURPOSE In the treatment of non–small-cell lung cancer (NSCLC) with a driver mutation,
the role of anti–PD-(L) 1 antibody after tyrosine kinase inhibitor (TKI) remains unclear. This …

Simple Summary The benefit of neoadjuvant chemoimmunotherapy was compared with
chemotherapy for localized NSCLC in several trials. We conducted a systematic review and …

Importance Immune checkpoint inhibitor (ICI) monotherapy with pembrolizumab and ICI plus
chemotherapy have been approved as first-line treatments for non–small cell lung cancer …

PERLA is a global, double-blind, parallel phase II trial (NCT04581824) comparing efficacy
and safety of anti–PD-1 antibodies dostarlimab and pembrolizumab, plus chemotherapy …

Living guidelines are developed for selected topic areas with rapidly evolving evidence that
drives frequent change in recommended clinical practice. Living guidelines are updated on …

Background In CheckMate 9LA, nivolumab plus ipilimumab with chemotherapy prolonged
overall survival (OS) versus chemotherapy regardless of tumor PD-L1 expression or …

Lung cancer is responsible for 1.8 million annual deaths. Non–small cell lung cancers
(NSCLC) represent 85% of lung cancer tumors. While surgery is an effective early-stage …